Intensity TherapeuticsINTS -0.78%28 PB Ratio is 1.03 as of Jun. 26, 2026. GuruFocus rates INTS with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,232 Biotechnology companies, Intensity Therapeutics ranks better than 81.41% on this metric.
The historical rank and industry rank for Intensity Therapeutics's PB Ratio or its related term are showing as below:
INTS'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1.04
Current: 1.03
During the past 7 years, Intensity Therapeutics's highest PB Ratio was 1.04. The lowest was 0.00. And the median was 0.00.
INTS's PB Ratio is ranked better than 81.41% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs INTS: 1.03
During the past 12 months, Intensity Therapeutics's average Book Value Per Share Growth Rate was -2.40% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Intensity Therapeutics was -85.20% per year. The lowest was -85.20% per year. And the median was -85.20% per year.
Back to Basics: PB Ratio
Intensity Therapeutics (NAS:INTS) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Intensity Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intensity Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intensity Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Intensity Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Intensity Therapeutics (INTS) has a PB Ratio of 1.03 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Intensity Therapeutics and its competitors. According to the industry distribution chart, Intensity Therapeutics ranks #229 out of 1232 companies in the Biotechnology industry, placing it in the top 18.6%.
Is Intensity Therapeutics' PB Ratio too high?
Intensity Therapeutics' current PB Ratio is 1.03. The Biotechnology industry median PB Ratio is 2.80. Intensity Therapeutics' value of 1.03 is 63.2% below this industry median. Based on the distribution chart, Intensity Therapeutics ranks #229 out of 1232 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Intensity Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Intensity Therapeutics' PB Ratio compare to BRTX and KPRX?
According to the Biotechnology industry distribution chart, Intensity Therapeutics ranks #229 out of 1232 companies for PB Ratio. This places Intensity Therapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Intensity Therapeutics' value of 1.03 is 63.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intensity Therapeutics's current PB Ratio of 1.03 is 63.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Intensity Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intensity Therapeutics's current PB Ratio is 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intensity Therapeutics stock overvalued right now?
Intensity Therapeutics (INTS) has a current PB Ratio of 1.03. The current PB Ratio is 1.03 and 63.2% below the Biotechnology industry median of 2.80. Intensity Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Intensity Therapeutics (INTS), the current PB Ratio is 1.03 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
28GF Score
Get the complete analysis for INTS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INTS has been successfully added to your 
